Linperlisib (YY-20394) 是一种有效的,具有口服活性的,效选择性 PI3Kδ 的抑制剂,来自专利 WO 2015055071 A1。Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC50 of 6.4 nM[1].
Linperlisib (YY-20394) 正在接受复发性和/或难治性滤泡性淋巴瘤的研究。
MCE has not independently confirmed the accuracy of these methods. They are for reference only
苏州凯若利新材料科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
凯若利销售